Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q1

4671.TEDINET S100RP4T
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥10.6bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥46.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥11.6bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥249m2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥681m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥303m2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥769m2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥292m2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥748m2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥124m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥442m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥124m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥442m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥37.1bnat 2023-06-30Cons.Assets
Total assets¥38.9bnat 2023-03-31Cons.Assets
Total assets¥38.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥11.2bnat 2023-06-30Cons.Liabilities
Total liabilities¥12.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥26.0bnat 2023-06-30Cons.Net assets
Net assets / equity¥26.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥23.6bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥9.6bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥12.6bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥11.072023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥215.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥42.322022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥11.052023-04-01 → 2023-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥214.032022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥42.252022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio69.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio61.5%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥145m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥6.6bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥6.6bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥0
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥348m
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥0
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥55m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥190m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥190m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥8m
—segment totalrevenue2023-04-01 → 2023-06-30¥10.6bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥10.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥0
—segment totalsegment profit2023-04-01 → 2023-06-30¥395m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥4m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥108m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥7.6bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.6bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥855m
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥102m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥102m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥73m
—segment totalrevenue2022-04-01 → 2022-06-30¥11.6bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥11.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥4m
—segment totalsegment profit2022-04-01 → 2022-06-30¥789m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 358
ItemContextValueUnit
Net assetsPrior1YearInstant26591000000JPY
Net assetsCurrentQuarterInstant25963000000JPY
Liabilities and net assetsPrior1YearInstant38893000000JPY
Liabilities and net assetsCurrentQuarterInstant37119000000JPY
Net salesPrior1YTDDuration11566000000JPY
Net salesCurrentYTDDuration10638000000JPY
Cost of salesPrior1YTDDuration7957000000JPY
Cost of salesCurrentYTDDuration7532000000JPY
Gross profitPrior1YTDDuration3609000000JPY
Gross profitCurrentYTDDuration3106000000JPY
Selling general and administrative expensesPrior1YTDDuration2928000000JPY
Selling general and administrative expensesCurrentYTDDuration2856000000JPY
Operating incomePrior1YTDDuration681000000JPY
Operating incomeCurrentYTDDuration249000000JPY
Dividends income noiPrior1YTDDuration50000000JPY
Dividends income noiCurrentYTDDuration29000000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration0JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration1000000JPY
Subsidy income noiPrior1YTDDuration23000000JPY
Subsidy income noiCurrentYTDDuration0JPY
Other noiPrior1YTDDuration23000000JPY
Other noiCurrentYTDDuration29000000JPY
Non operating incomePrior1YTDDuration97000000JPY
Non operating incomeCurrentYTDDuration60000000JPY
Interest expenses noePrior1YTDDuration5000000JPY
Interest expenses noeCurrentYTDDuration3000000JPY
Commission fee noePrior1YTDDuration1000000JPY
Commission fee noeCurrentYTDDuration1000000JPY
Early termination feePrior1YTDDuration1000000JPY
Early termination feeCurrentYTDDuration0JPY
Other noePrior1YTDDuration0JPY
Other noeCurrentYTDDuration1000000JPY
Non operating expensesPrior1YTDDuration9000000JPY
Non operating expensesCurrentYTDDuration7000000JPY
Ordinary incomePrior1YTDDuration769000000JPY
Ordinary incomeCurrentYTDDuration303000000JPY
Gain on sales of investment securities eiPrior1YTDDuration0JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration1000000JPY
Extraordinary incomePrior1YTDDuration0JPY
Extraordinary incomeCurrentYTDDuration1000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration3000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration10000000JPY
Loss on valuation of investment securities elPrior1YTDDuration18000000JPY
Loss on valuation of investment securities elCurrentYTDDuration－JPY
Other elPrior1YTDDuration－JPY
Other elCurrentYTDDuration1000000JPY
Extraordinary lossPrior1YTDDuration21000000JPY
Extraordinary lossCurrentYTDDuration12000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass